|
|
Research advance in the treatment of phenylketonuria |
ZHANG Lei, XU Xiao-Heng,ZHANG Si-Jin. |
Department of Pediatrics, the Second Hospital of Jilin University, Changchun 130041, China |
|
Cite this article: |
ZHANG Lei,XU Xiao-Heng,ZHANG Si-Jin. Research advance in the treatment of phenylketonuria[J]. 中国当代儿科杂志, 2009, 11(9): 786-789.
|
|
|
|
ZHANG Lei,XU Xiao-Heng,ZHANG Si-Jin. Research advance in the treatment of phenylketonuria[J]. CJCP, 2009, 11(9): 786-789.
|
URL: |
http://www.zgddek.com/EN/ OR http://www.zgddek.com/EN/Y2009/V11/I9/786 |
| [1]Scriver CR. Why mutation analysis does not always predict clinical consequences: explanations in the era of genomics[J]. J Pediatr, 2002, 140(5):502-506.
|
| [2]Weglage J, Wiedermann D, Denecke J, Feldmann R, Koch HG, Ullrich K, et al. Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria[J]. J Inherit Metab Dis, 2002, 25(6):431-436.
|
| [3]Giovannini M, Riva E, Salvatici E, Fiori L, Paci S, Verduci E, et al. Treating phenylketonuria: a single centre experience[J]. J Int Med Res, 2007, 35(6):742-752.
|
| [4]Macdonald A, Lee P, Davies P, Daly A, Lilburn M, Gokmen Ozel H, et al. Long-term compliance with a novel vitamin and mineral supplement in older people with PKU[J]. J Inherit Metab Dis, 2008, 31(6):718-723.
|
| [5]Koch R, Moseley KD, Yano S, Nelson M Jr, Moats RA. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment[J]. Mol Genet Metab, 2003, 79(2):110-113.
|
| [6]Bik-Multanowski M, Didycz B, Mozrzymas R, Nowacka M, Kaluzny L, Cichy W, et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet[J]. J Inherit Metab Dis, 2009, 32(1):126.
|
| [7]Sitta A, Barschak AG, Deon M, de Mari JF, Barden AT, Vanzin CS, et al. L-carnitine blood levels and oxidative stress in treated phenylketonuric patients[J]. Cell Mol Neurobiol, 2009, 29(2):211-218.
|
| [8]Leuzzi V, Pansini M, Sechi E, Chiarotti F, Carducci C, Levi G, et al. Executive function impairment in early-treated PKU subjects with normal mental development[J]. J Inherit Metab Dis, 2004, 27(2):115-125.
|
| [9]MacDonald A, Daly A, Davies P, Asplin D, Hall SK, Rylance G, et al. Protein substitutes for PKU: what′s new? [J]. J Inherit Metab Dis, 2004, 27(3):363-371.
|
| [10]Kim W, Erlandsen H, Surendran S, Stevens RC, Gamez A, Michols-Matalon K, et al. Trends in enzyme therapy for phenylketonuria[J]. Mol Ther, 2004, 10(2):220-224.
|
| [11]Levy HL. Phenylketonuria: old disease, new approach to treatment[J]. Proc Natl Acad Sci USA, 1999, 96(5):1811-1813.
|
| [12]Ikeda K, Schiltz E, Fujii T, Takahashi M, Mitsui K, Kodera Y, et al. Phenylalanine ammonialyase modified with polyethylene glycol: potential therapeutic agent for phenylketonuria[J]. Amino Acids, 2005, 29(3):283-287.
|
| [13]Kanai Y, Endou H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity[J]. J Toxicol Sci, 2003, 28(1):1-17.
|
| [14]Matalon R, Surendran S, Matalon KM, Tyring S, Quast M, Jinga W, et al. Future role of large neutral amino acids in transport of phenylalanine into the brain[J]. Pediatrics, 2003, 112(6 Pt 2):1570-1574.
|
| [15]Steinfeld R, Kohlschutter A, Ullrich K, Lukacs Z. Efficiency of long-term tetrahydrobiopterin monotherapy in phenylketonuria[J]. J Inherit Metab Dis, 2004, 27(4):449-453.
|
| [16]Perez-Duenas B, Vilaseca MA, Mas A, Lambruschini N, Artuch R, Gómez L, et al. Tetrahydrobiopterin responsiveness in patients with phenylketonuria[J]. Clin Biochem, 2004, 37(12):1083-1090.
|
| [17]Doggrell SA. Is sapropterin treatment suitable for all subjects with phenylketonuria?[J]. Expert Opin Pharmacother, 2008, 9(1):145-147.
|
| [18]Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study[J]. Lancet, 2007, 370(9586):504-510.
|
| [19]Burnett JR. Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria[J]. IDrugs, 2007, 10(11):805-813.
|
| [20]Blau N, Erlandsen H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency[J]. Mol Genet Metab, 2004, 82(2):101-111.
|
| [21]Eisensmith RC, Woo SL. Gene therapy for phenylketonuria[J]. Acta Paediatr, 1994, 407:124-129.
|
| [22]Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J, et al. Reversal of hypopigmentation in phenylketonuria mice by adenovirusmediated gene transfer[J]. Pediatr Res, 1999, 45(4 Pt 1):465-473.
|
| [23]Eavri R, Lorberboum-Galski H. A novel approach for enzyme replacement therapy[J]. J Bio Chem, 2007, 282(32):23402-23409.
|
| [24]Jung SC, Park JW, Oh HJ, Choi JO, Seo KI, Park ES, et al. Protective effect of recombinant adeno-associated virus 2/8-mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria[J]. J Korean Med Sci, 2008, 23(5):877-883.
|
| [25]Christensen R, Alhonen L, Wahlfors J, Jakobsen M, Jensen TG. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin[J]. Exp Dermatol, 2005, 14(7):535-542.
|
| [26]Harding CO, Neff M, Jones K, Wild K, Wolff JA. Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice[J]. J Gene Med, 2003, 5(11):984-993.
|
| [27]Pey AL, Ying M, Cremades N, Velazquez-Campoy A, Scherer T, Thony B, et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria[J]. J Clin Invest, 2008, 118 (8):2858-2867.
|
| [28]Nascimento C, Leandro J, Tavares de Almeida I, Leandro P. Modulation of the activity of newly synthesized human phenylalanine hydroxylase mutant proteins by low-molecular-weight compounds[J]. Protein J, 2008, 27(6):392-400.
|
[1] |
MA Yan-Yan, SONG Jin-Qing, WU Tong-Fei, LIU Yu-Peng, XIAO Jiang-Xi, JIANG Yu-Wu, YANG Yan-Ling. Leucodystrophy induced by late onset 3-hydroxy-3-methylglutaric aciduria[J]. 中国当代儿科杂志, 2011, 13(5): 392-395. |
[2] |
CHEN Yin-Bo, HAO Yun-Peng, LIANG Dong. Hypomelanosis of Ito and brain abscess in a boy[J]. 中国当代儿科杂志, 2011, 13(5): 440-441. |
[3] |
ZHU Xue-Ming, JIN Mei-Fang, WANG Xin-Dong, LI Ying, LI Xiao-Zhong. Familial hemophagocytic lymphohistiocytosis complicated by thymic dysplasia: a case report[J]. 中国当代儿科杂志, 2009, 11(12): 939-940. |
[4] |
ZHU Li-Na, LIU Xin, WANG Chun-Zhi, WANG Yan, YANG Xiao, PENG Wei, WANG Wei, MA Ning. RABL2B gene mutation in a girl with mental retardation and hyperactivity[J]. 中国当代儿科杂志, 2009, 11(9): 780-781. |
[5] |
ZHANG Lei, XU Xiao-Heng, ZHANG Si-Jin. Research advance in the treatment of phenylketonuria[J]. 中国当代儿科杂志, 2009, 11(9): 786-789. |
[6] |
JIANG Feng-Zhi, CUI Qi-Liang, JIANG Jian-Hui. A case report of maple syrup urine disease[J]. 中国当代儿科杂志, 2009, 11(07): 599-600. |
[7] |
WEI Xiao-Qiong, KONG Qing-Peng, ZHANG Yao, YANG Yan-Ling, CHANG Xing-Zhi, QI Yu, QI Zhao-Yue, XIAO Jiang-Xi, QIN Jiong, WU Xi-Ru. A case of Leigh syndrome associated with respiratory chain complex I deficiency due to mitochondrial gene 13513G>A mutation[J]. 中国当代儿科杂志, 2009, 11(05): 333-336. |
[8] |
CHEN Wei, LIAO Jian-Xiang, CHEN Li. Rett syndrome in a child treated with adrenocorticotrophic hormone[J]. 中国当代儿科杂志, 2009, 11(03): 235-236. |
[9] |
ZHANG Li-Xia, GAO Ping-Ming. A case report of carnitine palmitoyltransferase II deficiency[J]. 中国当代儿科杂志, 2009, 11(02): 162-162. |
[10] |
LI Ji, QIU Zheng-Qing, WEI Min. Caroli's syndrome[J]. 中国当代儿科杂志, 2009, 11(01): 10-14. |
[11] |
BAI Fan, REN Li-Hong, ZHANG Hai-Tao, AN Hui-Ping, HUANG Su-Fang, HU Meng-Ying. Neurofibromatosis type 1: a report of 4 cases in a family constellation[J]. 中国当代儿科杂志, 2006, 8(5): 437-438. |
|
|
|
|